Cytokinetics, Inc. (CYTK) Receives Orphan Drug Designation from European Medicines Agency
Cytokinetics, a clinical-stage biopharm company developing novel small molecule therapeutics for the potential treatment of serious diseases and medical conditions, today announced that the European Medicines Agency (EMA) has granted the company’s lead drug candidate CK-2017357 orphan medicinal product designation for the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s Disease. CK-2017357 is currently in phase II clinical development program in patients with ALS, and has also been granted orphan drug designation by the U.S. Food and Drug Administration for the potential treatment of ALS, a debilitating disease of neuromuscular impairment. Orphan drug designation offers several potential…